Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

Scientific exchange · Dr. Gabriel Ueda

22 Jul 2026 · In person · Dr. Gabriel Ueda, National Cancer Center Tokyo · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0029—

Capture insight from this engagement

Location: National Cancer Center Tokyo
Therapeutic area: Oncology
Country: Japan
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Comparator checkpoint monotherapy
PD-L1 testing turnaround

Scientific content used

PD-L1 testing pathway infographic
VOYAGE-1 pivotal data summary

Questions raised

How should grade 2 infusion reactions be managed without steroids?

Notes

Scientific exchange with radiation oncologist at National Cancer Center Tokyo. Discussed comparator checkpoint monotherapy, pd-l1 testing turnaround.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 2
Depth of exchange: 4
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0029

Audit history (1)

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
05 Sept 2026, 13:04 UTC	Update	LOLuis Ortega	summary	In progress → In progress	—	UI